Home » ADVANCIS TO CONDUCT ADDITIONAL ADULT AMOXICILLIN TRIAL
ADVANCIS TO CONDUCT ADDITIONAL ADULT AMOXICILLIN TRIAL
Advancis Pharmaceutical announced that it will conduct a new Phase III trial for its Amoxicillin PULSYS product candidate in adults and adolescents with pharyngitis/tonsillitis due to Group A strep infections. Enrollment in the clinical trial is expected to begin in the fourth quarter of 2005.
Advancis' pivotal trial is expected to be designed as a 600-patient, double-blind, double-dummy, non-inferiority trial. The company anticipates comparing its Amoxicillin PULSYS dosage form, delivered in a once-daily, 775 mg tablet for a period of 10 days, to 250 mg of penicillin dosed four times daily.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May